Table 3.

Univariate analysis for response assessment at day+30 and day+90 after eltrombopag

	Hazard ratio	p	30-day expected events (SE)	90-day expected events (SE)
Age (per decade)	0.875	0.136
26-year			0.62 (0.063)	1.94 (0.15)
50-year			0.45 (0.15)	1.41 (0.2)
Sex	0.937	0.826
Male			0.51 (0.06)	1.58 (0.19)
Female			0.54 (0.09)	1.68 (0.26)
Duration of ITP (years)	1 (per 1 log year)	0.999
1-year			0.52 (0.05)	1.62 (0.17)
6-year			0.52 (0.06)	1.62 (0.21)
Prior therapy	1.164	0.612
≤3 prior lines of therapy			0.51 (0.8)	1.57 (0.22)
>3 prior lines of therapy			0.6 (0.08)	1.82 (0.28)
Splenectomy	0.846	0.688
Yes			0.54 (0.03)	1.67 (0.18)
No			0.45 (0.18)	1.42 (0.58)
Hemoglobin (g/dL)	0.955	0.458
11.7			0.55 (0.04)	1.72 (0.11)
14.9			0.48 (0.06)	1.48 (0.18)
WBC (/μL)	0.892 (per 1000 WBC/μL )	0.066
6700			0.64 (0.09)	2.06 (0.23)
10000			0.44 (0.05)	1.41 (0.16)
Paltelets	1.03 (per 1000 platelets/μL)	0.077
≤5000			0.42 (0.09)	1.36 (0.21)
17000			0.59 (0.04)	1.94 (0.14)
Eltrombopag dose	1	0.566
25 mg			0.52 (0.05)	1.49 (0.15)
50 mg			0.61 (0.09)	1.75 (0.27)